Customised assay development

During early drug development, customised assays and screens are often required.  This may relate to a specific target, eg. the development of a reporter assay to assess the binding of ligands to their receptor, or alternatively an improvement to an existing assay may be required to improve the speed or sensitivity.

CXR Biosciences has highly qualified staff across a range of disciplines that can rapidly design and develop innovative new assays and approaches to address every possible issue in drug safety.  The unique combination of 'traditional' preclinical development expertise with state of the art molecular biology enables CXR to design and deliver assays that exactly match the clients' requirements.

These capabilities include;

• State of the art LC/MS/MS to improve sensitivity and speed of analysis
• Cloning drug or toxicity targets to develop high-throughput in vitro screens
• Transcriptional profiling to identify unknown targets to understand mechanism of action and/or mechanism of toxicity
• Cloning novel targets to understand mechanism of toxicity
• Developing novel in vitro and in vivo reporter systems to understand mechanism of drug action / toxicity